D'Silva Andrew J., Chief Business Officer of OptimizeRx Corp, has reported a transaction involving the acquisition of shares in the company. This event is significant as it showcases the ongoing activity of key executives and their management of stock compensation within the business services sector.
Background
OptimizeRx Corp is a company based in Waltham, Massachusetts, specializing in business services. The company is incorporated in Nevada and operates under the Central Index Key (CIK) 0001448431. It is classified under the Standard Industrial Classification (SIC) for services in business services, not elsewhere classified (SIC Code: 7389). Recent filings show that D'Silva has been actively engaging in stock transactions, with the latest filing dated October 2, 2026.
What the Filing Says
According to the recent SEC filing (accession number 0001628280-26-064386), D'Silva reported a transaction on October 1, 2026, involving 414 shares of common stock. The filing states, "These shares were withheld by the Issuer upon the vesting of restricted stock units to satisfy the Reporting Person's tax withholding obligations." Following this transaction, D'Silva holds a total of 99,246 shares in OptimizeRx Corp.
Impact
This transaction may have implications for OptimizeRx's stakeholders, including other executives and shareholders. As executives manage their stock compensation, it reflects broader trends in the business services industry regarding executive remuneration and tax obligations. Observers in the sector may consider how similar actions by other companies could influence their own practices.
What's Next
The filing does not say what happens next.